EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Extended thrombotic prophylaxis in COVID-19 early discharge: A retrospective cohort study

Sebastiaan T Van't Hoff iD, Gea Helfrich, Sanne Boerman, Hans A Hardeman

PLOS One · 2026

DOI: 10.1371/journal.pone.0340889 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift PLOS One, 2026. Verfasst von Sebastiaan T Van't Hoff und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Amphia Hospital, Breda, the Netherlands. Hauptthemen laut MEDLINE: COVID-19, Nadroparin, Anticoagulants, Venous Thrombosis. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction/Background Due to limits in available staff and space during the COVID-19 pandemic, home monitoring programmes were introduced, reducing strain on resources, and preventing readmissions. Several hospitals included prophylaxis for venous thrombotic events (VTE), as COVID-19 appeared to be thrombogenic. Other hospitals did not, expecting patients to be more mobile while at home. Our aim was to determine whether the administration of nadroparin has led to a difference in VTE occurrence between two groups of previously included patients. Materials and methods Retrospective cohort study of two cohorts included in home monitoring with the same protocol, except for nadroparin prophylaxis.

Results

663 patients were analysed in equal groups from two hospitals. No significant difference was found in occurrence of VTE after discharge, readmissions in general or readmissions due to VTE in otherwise comparable groups.

Discussion

As opposed to trials determining thrombotic prophylaxis was of benefit after discharge due to COVID-19, we found no difference between our groups. Our study was retrospective and comprised data compiled over almost two years, which provides a relatively large sample size and overview through different treatment regimes.

Conclusion

For the future, thrombotic prophylaxis for COVID-19 home monitoring might not be indicated and reconsidered for different home monitoring programmes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19NadroparinAnticoagulantsVenous ThrombosisVenous ThromboembolismHumansRetrospective StudiesPatient DischargeFemaleMaleMiddle AgedAgedSARS-CoV-2Patient Readmission

Substanzen

NadroparinAnticoagulants

Autor:innen und Institutionen

  • Department of Pulmonary Medicine, Amphia Hospital, Breda, the Netherlands.
  • Department of Pulmonary Diseases, Maasstad Hospital, Rotterdam, the Netherlands.
  • Department of Pulmonology, St. Antonius Hospital, Nieuwegein, the Netherlands.

ORCID-Profile: Sebastiaan T Van't Hoff

Zitieren

APA

Van't Hoff, S. T., Helfrich, G., Boerman, S., & Hardeman, H. A. (2026). Extended thrombotic prophylaxis in COVID-19 early discharge: A retrospective cohort study. PLOS One. https://doi.org/10.1371/journal.pone.0340889

Vancouver

Van't Hoff ST, Helfrich G, Boerman S, Hardeman HA. Extended thrombotic prophylaxis in COVID-19 early discharge: A retrospective cohort study. PLOS One. 2026. doi:10.1371/journal.pone.0340889

BibTeX
@article{VantHoff2026,
  author = {Van't Hoff, Sebastiaan T and Helfrich, Gea and Boerman, Sanne and Hardeman, Hans A},
  title = {Extended thrombotic prophylaxis in COVID-19 early discharge: A retrospective cohort study},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0340889}
}
Kostenlos starten →